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Abstract
Background: N-terminal-pro brain natriuretic peptide (NT-
proBNP) is a useful cardiac marker that is also influenced
by renal dysfunction. It was our objective to assess the rela-
tionship between NT-proBNP concentrations in plasma and
worsening renal function, and to attempt adjustment of NT-
proBNP for renal dysfunction in a prospective, stratified
multi-center study.
Methods: We stratified 203 male patients according to their
cardiac status and the estimated glomerular filtration rate
(eGFR). Cardiac disease was assessed by medical history,
physical examination and standardized echocardiography.
Patients were stratified according to the following: absence
of cardiac history and abnormalities (control, CTRL, ns66),
cardiac history without left ventricular hypertrophy (LVH) or
left ventricular systolic dysfunction (LVD) (history, ns30),
LVH without systolic dysfunction (LVH, ns68), and LVD
wejection fraction (EF) -40%, LVD, ns39x. Renal disease
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was stratified according to the eGFR: 15–30 mL/min
(ns52), 31–75 mL/min (ns99), and )75 mL/min (ns52).
Results: NT-proBNP was correlated with eGFR in the entire
study population and for all levels of cardiac disease (all
p-0.01). Regression analysis allowed adjustment of NT-
proBNP for eGFR in a continuous manner, and this adjust-
ment significantly improved the predictive value (receiver
operating characteristic curve for symptomatic LVD from
0.80 to 0.86, p-0.01; sensitivity from 74% to 83% and spec-
ificity from 68% to 79%).
Conclusions: NT-proBNP correlates inversely and signifi-
cantly with eGFR throughout all levels of cardiac strata. We
propose for the first time a continuous adjustment algorithm
which markedly improves the predictive values of NT-
proBNP in male patients with impaired renal function.
Clin Chem Lab Med 2010;48:121–8.
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Introduction
N-terminal-pro brain natriuretic peptide (NT-proBNP) is a
useful cardiac marker that may facilitate the early diagnosis
of heart failure and stratification of cardiac risk. Specifically,
NT-proBNP has been shown to be useful for the diagnosis
of left ventricular (LV) systolic (1–6) as well as diastolic
dysfunction (7, 8), and acutely decompensated heart failure
(9–13). While NT-proBNP plasma concentrations are pri-
marily thought to indicate the severity of LV dysfunction,
recent studies have shown that concentrations also correlate
inversely with the glomerular filtration rate (GFR) and may
be highly increased in patients on dialysis (14–17).
The influence of renal dysfunction on NT-proBNP is high-
ly relevant for the clinical application of this marker since
cardiac disease is frequently associated with renal disease
(14, 18–20). Likewise, patients with chronic kidney disease
(CKD) are at increased risk of suffering from cardiovascular
complications, such as myocardial infarction (MI) and heart
failure (21–23). Therefore, patients with known or suspected
cardiac disease as well as patients with renal disease are
potential candidates for NT-proBNP testing.
Although cardiac markers are utilized more and more fre-
quently in these patient groups and concomitant renal dys-
function may distort the correct interpretation of individual
test results, no algorithm for adjustment of measured NT-
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proBNP concentrations for renal dysfunction has been estab-
lished to date. Indeed, patients with more than mild renal
dysfunction are often excluded from clinical studies (9, 10).
Therefore, our objective was to assess the effect of renal
function on NT-proBNP concentrations, and to establish for
the first time an algorithm that allows adjustment of meas-
ured NT-proBNP concentrations with respect to renal dys-
function. We hypothesized that NT-proBNP would correlate
inversely with estimated glomerular filtration rate (eGFR),
and that adjustment of NT-proBNP according to the severity
of renal disease would increase the predictive power of this
marker. To test our hypothesis, we conducted a cross-sec-
tional study of male individuals with prospective stratifica-
tion according to the degree of cardiac disease and the degree
of kidney disease. All study subjects were well characterized
by careful physical examination, medical history, and stan-
dardized echocardiography.
Materials and methods
Patients
In this cross-sectional study, a total of 204 clinically stable male
patients between 18 and 75 years of age with an eGFR G15 mL/
min (not on dialysis) were enrolled in four centers in Germany.
Patients were stratified into the following groups according to their
cardiac condition: 1) absence of LV hypertrophy (LVH) and absence
of LV systolic dysfunction (LVD) during echocardiography (ns96),
2) LVH with preserved LV systolic function (LVH, ns68) or
3) presence of LVD wejection fraction (EF)-40%, LVD, ns39x.
One patient could not be stratified and was excluded from further
analyses. Among the 96 patients without LVH and without LVD,
30 patients had a reported previous history of cardiac disease includ-
ing MI or )2nd degree valvular disease and constituted the ‘‘His-
tory’’ group. In this group, quantitative echocardiography was
available in all but one patient (ns29). The remaining 66 patients
without LVH and LVD had no previous history of any cardiac dis-
ease and constituted the control group (CTRL). eGFR was calcu-
lated using the Cockroft-Gault formula (24) and patient counts were
ns52 for eGFR 15–30 mL/min, ns99 for eGFR 31–75 mL/min
and ns52 for eGFR )75 mL/min.
During a visit to one of the four study centers either as out-
patients or during an in-hospital stay, all patients underwent a stan-
dardized interview, physical examination including blood and urine
collection and standardized echocardiography. Patients with unstable
angina pectoris, MI, or decompensated heart failure within 4 weeks,
or patients with severe pulmonary hypertension (estimated systolic
pulmonary artery pressure G50 mm Hg by echocardiography) were
also excluded from the study. All study procedures were performed
in accordance with GCP/ICH guidelines and the study protocol was
accepted by local Ethics Committees. All patients gave written
informed consent.
Biochemical analyses
Serum creatinine, creatine kinase (CK), erythrocyte count, hemat-
ocrit and hemoglobin and urine protein and creatinine were meas-
ured using standard clinical laboratory procedures. Several formulas
have been developed to estimate renal function from measurements
of serum creatinine, the two most frequently used being the Cock-
croft-Gault formula and the Modification of Diet in Renal Disease
(MDRD) four variable equation. While the latter is more widely
used for automated reporting eGFR values since it does not require
body weight, we used the Cockcroft-Gault formula which includes
body weight to provide estimates of creatinine clearance rates. A
recent comparison of measured GFR using continuous inulin infu-
sion with values derived by the Cockcroft-Gault and the MDRD
formulas revealed similar accuracies for both (25).
NT-proBNP concentrations were measured by a central laboratory
using the Elecsys-system from Roche Diagnostics (Mannheim,
Germany). The reference interval for normal NT-proBNP used in
this study was derived from an age and gender stratified reference
sample of 2948 healthy blood donors (data at Roche Diagnostics).
In a male subgroup of this reference sample with a median age of
56.3 years (ns432), the 97.5th percentile for NT-proBNP was
193.5 pg/mL. Since our male study population was of similar age
(mean 56.1 years, median 59.0 years) we chose this cut-off thresh-
old as the upper limit of normal for the present study (reference
cut-off).
Echocardiography
Echocardiography (ECG) was performed according to criteria of the
American Society of Echocardiography (26) following a predefined
protocol by a single experienced investigator at each site. Video-
tapes were recorded for each patient and a core laboratory performed
all quantitative measurements, including EF. Standard measurements
included end diastolic thickness of septum and LV posterior wall as
well as end diastolic and end systolic LV diameter. Left ventricular
mass (LVM) was calculated as LVMwgxs0.8(1.04)((IVSqLVIDq
LVPW)3yLVID3)q0.6 according to Devereux et al. (27). LVM was
indexed to body surface area and LVH was defined as LVM index
)130 g/m2. Left ventricular end diastolic volume (LVEDV) and
end systolic volume (LVESV) were determined by the area-length
method (28) from an ECG-triggered 2D-image in the 4-chamber
view, and EF was calculated as EFs(LVEDVyLVESV)=
100/LVEDV. Systolic LV dysfunction was defined as an EFF40%.
Systolic pulmonary artery pressure was estimated in the presence
of tricuspid regurgitation as central venous pressureqsystolic pres-
sure gradient between the right ventricle and right atrium.
Statistics
Comparison of baseline characteristics between study groups was
performed using ANOVA for continuous variables and the x2-test
for categorical variables. Since the distribution of NT-proBNP con-
centration is skewed, logarithmically transformed values were used
for subsequent analyses. To determine the effect of eGFR on NT-
proBNP, regression analyses were performed with NT-proBNP as
the dependent variable and eGFR, as well as a number of other
covariates as independent variables. The final model included
eGFR, LVEF, LV end diastolic volume index (LVEDVI), New York
Heart Association (NYHA) classification and the presence of rales,
and was used to adjust measured NT-proBNP concentrations for
eGFR. The resulting adjustment algorithm was: NT-pro-
BNPadjustedsNT-proBNP/e1.892–0.025*eGFR. The predictive values of
both crude and adjusted NT-proBNP were calculated for the detec-
tion of LVD and symptomatic LVD both for the reference cut-off
(193.5 pg/mL) which was derived from the 97.5th percentile of a
large healthy reference population (see above), as well as by receiv-
er operator characteristic (ROC) analysis without pre-specified cut-
points. Calculations were performed using SAS 8.2 and SPSS 12.0
statistical software (SPSS Inc., Chicago, IL, USA).
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Table 1 Demographics of patients stratified according to cardiac disease.
CTRL History LVH LVD
n 66 30 68 39
Age, years 49.3"1.7a 57.7"2.2 57.7"1.5 63.8"1.4
BMI, kg/m2 25.9"0.5 26.7"0.6 26.6"0.5 28.5"0.6
eGFR, mL/min 57.7"4.3 60.9"5.4 44.6"3.0a 60.5"4.7
History of heart disease 0 (0%)a 30 (100%) 22 (32.4%) 36 (92.3%)
History of MI 0 (0%)a 20 (20.8%) 15 (22.1%) 24 (61.5%)
NYHA class 1.2"0.07a 1.8"0.12 1.4"0.07 2.2"0.1
Presence of rales 4 (6.1%) 3 (10.0%) 2 (2.9%) 6 (15.4%)
Ejection fraction, % 61.6"1.4 62.0"2.0 61.1"1.2 32.1"1.0a
LVEDVI, mL/m2 58.1"1.6 59.5"1 69.1"2 103.2"5a
LVMI, g/m2 103.6"2.0 104.1"2.4 157.9"2.5a 154.6"7.0a
Renal transplant 29 (43.9%)a 7 (23.3%) 28 (41.2%)a 1 (2.6%)
Diabetes mellitus 13 (19.7%) 10 (33.3%) 14 (20.6%) 19 (48.7%)a
Arterial hypertension 59 (89.9%) 23 (76.7%) 62 (91.2%) 25 (64.1%)
Hemoglobin, g/dL 12.8"0.3 13.4"0.3 12.2"0.3 13.7"0.3
CTRL, absence of cardiac history and LVH and LVD; history, presence of cardiac history but without LVH or LVD; LVH, LVH only (i.e.
absence of LVD); LVD; LVD (EFF40%). Demographic data are given as mean"standard error for continuous variables or n (%) for
categorized variables. aSignificant differences vs. other strata by ANOVA.
Results
Patient characteristics
Stratification according to cardiovascular comorbidities
revealed a high prevalence of arterial hypertension in all
groups, particularly in those with LVH (Table 1). Patients
with systolic LVD also showed a high degree of LVH and
were older. Mean EF in this group was 32% as compared to
a mean EF of over 60% in all other groups. This group also
showed significant LV dilatation and a high previous history
of heart disease. Due to stratification, the severity of CKD
was almost evenly distributed among the groups with or
without cardiac abnormalities.
Correlation of NT-proBNP with eGFR
Within cardiac disease groups, there was a wide scatter of
NT-proBNP concentrations with a minimum value of 5 and
a maximum value of 24,171 pg/mL. Significant negative cor-
relation was found for NT-proBNP and eGFR in the entire
study population (R2s0.236; p-0.0001), and in each pre-
defined group stratified by cardiac status (Figure 1). Accord-
ingly, although statistically significant differences between
the cardiac groups were observed, a wide overlap of NT-
proBNP concentrations was present (Figure 2, left).
Testing the interaction between cardiac disease and eGFR
showed that the correlation of both, cardiac disease and
eGFR with NT-proBNP was independent from each other.
This indicates that eGFR greatly affects measured NT-
proBNP concentrations regardless of the presence of cardiac
disease. Multivariate regression models with NT-proBNP as
dependent variable were evaluated. These models included
eGFR, EF, LVMI and LVEDVI, as well as a number of clin-
ical and anamnestic variables. The best prediction of NT-
proBNP was found in a model that included eGFR, EF,
LVEDVI (continuous variables), as well as NYHA-class
(I–IV) and rales (yes or no) (Table 2). In this model, eGFR
had a strong influence on NT-proBNP-concentrations which
was not abolished by the other covariates. Using the regres-
sion coefficient determined for the correlation between eGFR
and NT-proBNP from this model, NT-proBNP values were
calculated for each individual that were adjusted for eGFR.
The resulting adjustment algorithm was:
1.892–0.025=eGFRNT-proBNP sNT-proBNP/e .adjusted
A comparison of the lower adjusted with the higher crude
NT-proBNP concentrations demonstrates markedly less over-
lap between the subgroups and particularly better distinction
of LVD (Figure 2, right).
Abundance of reclassification and characteristics
of reclassified patients
In several patients with increased measured NT-proBNP con-
centrations above the reference cut-point (193.5 pg/mL,
derived from the reference population), mathematical adjust-
ment decreased the NT-proBNP to below the reference cut-
point and into the normal range. The frequency of
reclassification from elevated to normal was 21% for all sub-
jects with an eGFR of 31–75 mL/min, and 23% of all sub-
jects with an eGFR -30 mL/min. These reclassified patients
showed disease characteristics that were similar to individ-
uals with low unadjusted NT-proBNP concentrations (Table
3). Specifically, there was no indication for a significant
excess of cardiac disease in the group with normal NT-
proBNP after adjustment (better EF, only slightly higher
LVMI), however, eGFR was much lower in this group. This
finding indicates that in these patients, renal dysfunction was
indeed the underlying cause for measured NT-proBNP con-
centrations above the cut-off threshold.
Following adjustment of NT-proBNP for eGFR, a total of
81 patients with an LVEF )40% still exhibited increased
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Figure 1 Univariate correlations between eGFR and ln-transformed NT-proBNP in patient groups stratified according to cardiac disease
status.
CTRL denotes absence of cardiac history and LVH and LVD; history, presence of cardiac history but absence of LVH or LVD; LVH, LV
hypertrophy only (i.e., absence of LV dysfunction); LVD, LV dysfunction (EFF40%).
Figure 2 Box and whiskers plot of measured (left) and adjusted (right) log-transformed NT-proBNP concentrations in patient groups
stratified according to cardiac disease status.
CTRL denotes absence of cardiac history and LVH and LVD; history, presence of cardiac history but absence of LVH or LVD; LVH,
LV hypertrophy only (i.e., absence of LV dysfunction); LVD, LV dysfunction (EFF40%). *p-0.01 vs. CTRL, **p-0.01 vs. history,
***: p-0.01 vs. LVH.
Table 2 Determinants of NT-proBNP as assessed by adjusted
regression analysis.
Covariate b-Coefficient SE p-Value
eGFR, mL/min –0.025 0.00287 -0.0001
LVEF, % –0.022 0.00861 0.0117
LVEDVI, mL/m2 0.012 0.00432 0.0063
NYHA class (I–IV) 0.462 0.16299 0.0051
Rales (yes vs. no) 0.908 0.34911 0.0101
Intercept 7.15 0.8136 -0.0001
R2s0.53 Fs36.4
Results from adjusted regression analysis with log(NT-proBNP) as
the dependent variable; SE, standard error.
NT-proBNP concentrations. Since increased NT-proBNP has
been shown to be associated with diseases other than systolic
LVD or overt heart failure, we assessed which comorbidities
were present in these patients. Among these patients, 41.3%
showed LVH, 21.3% had long standing arterial hypertension,
20.0% had a moderately impaired LV systolic function
(40%-EFF50%), 10% had a previous MI with preserved
systolic function, and 3.7% had pulmonary disease. Thus, in
addition to significant systolic LVD, moderate LVD, LVH,
previous MI with preserved LV function and arterial hyper-
tension with no apparent cardiac abnormality are frequently
associated with increased NT-proBNP in patients with
decreased renal function.
Predictive values of crude and adjusted
NT-proBNP
Adjusted NT-proBNP concentrations were used in parallel to
unadjusted NT-proBNP concentrations to predict systolic
LVD and symptomatic LVD. The adjusted NT-proBNP con-
centrations were associated with a marked improvement in
predictive values compared to the actual measured values.
Specifically, the ROC areas for the detection of LVD, as well
as for symptomatic LVD, increased significantly (Table 4).
When the predictive values were compared to each other
at the reference cut-point (193.5 pg/mL), adjustment did not
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Table 3 Characteristics of patients with normal measured NT-proBNP as compared with patients with high measured NT-proBNP con-
centrations, but normal adjusted NT-proBNP.
NT-proBNP normal Increased measured
NT-proBNP, but normal
adjusted NT-proBNP
n 52 33
Age, years 48.7"1.7 55.1"2.7a
eGFR, mL/min 77.9"4.7 35.6"2.6a
EF, % 59.6"1.4 65.2"1.9a
LVMI, g/m2 112.3"3.2 126.8"6.9a
LVEDVI, mL/m2 58.8"1.9 61.1"2.8
LVH 14 (26.9%) 12 (36.4%)
Heart rate, bmp 72.5"1.2 73.9"1.5
Previous MI 11 (21.2%) 5 (15.2%)
Anamnestic other heart disease 9 (17.3%) 7 (21.2%)
Anamnestic heart failure 10 (19.2%) 3 (9.1%)
Pulmonary hypertension 0 0
Valvular disease 0 0
Arterial hypertension 45 (86.5%) 29 (87.9%)
ap-0.05 vs. normal crude NT-proBNP. Anamnestic other heart disease includes coronary artery disease, dilated cardiomyopathy, valve
replacement, arterial hypertension, atrial fibrillation.
Table 4 Effect of adjustment for renal impairment on NT-proBNP predictive value.
Condition NT-proBNP Cases/cohort ROC-area (95% CI) Sensitivity/ PPV/ Cut-off, pg/mL
specificity, % NPV, %
LVD Crude 39/202 0.77 (0.69–0.84) 95/30 26/96 193.5 (reference)
72/68 35/91 731a
Adjusted dto. 0.82 (0.76–0.89)b 95/51 32/98 193.5 (reference)
77/77 45/93 473a
LVD-Sympt Crude 35/202 0.80 (0.73–0.87) 100/30 25/100 193.5 (reference)
74/68 33/93 731a
Adjusted dto. 0.86 (0.80–0.91)b 100/49 30/100 193.5 (reference)
83/79 45/96 538a
LVD, EF-40% by echocardiography; LVD-Sympt.; symptomatic LVD; ROC, receiver operator characteristic; CI, confidence interval;
PPV, positive predictive value; NPV, negative predictive value; reference, pre-specified cut-point corresponding to 97.5th percentile of
healthy reference population. aPredictive values and corresponding cut-point derived from ROC analysis for highest pair of sensitivity
and specificity. bp-0.01 for comparison of ROC-areas.
diminish the sensitivity of the test, which was already at 95%
for the detection of LVD and 100% for the detection of
symptomatic LVD. However, specificity increased by ;20%
without any loss of sensitivity because the rate of false pos-
itives was markedly decreased (Table 4, compare lines 1 and
3 for LVD and 5 and 7 for symptomatic LVD, respectively).
When optimal sensitivity, specificity and cut-point were
computed using ROC analysis independently from the ref-
erence cut-point, adjustment of NT-proBNP was associated
with a marked increase in sensitivity and specificity (each
;5%) as compared to actual measured values (Table 4, com-
pare lines 2 and 4 for LVD and 6 and 8 for symptomatic
LVD, respectively).
Discussion
The current study addresses the effect of decreased renal
function on NT-proBNP as a marker of LVD in prospectively
stratified male patients. It demonstrates that in addition to
the severity of cardiac disease, renal impairment is a major
contributor to NT-proBNP concentrations. To improve the
predictive properties of NT-proBNP for cardiac disease, a
correction factor is proposed that allows adjustment of meas-
ured NT-proBNP concentrations according to the eGFR. This
adjustment improves the predictive values of the marker to
detect LVD and can help decrease false positive results.
Correlation between NT-proBNP and renal
function
NT-proBNP was correlated with eGFR in all groups of male
patients with and without cardiac disease. This finding cor-
roborates some very recent observational studies that indi-
cated a correlation between NT-proBNP and eGFR in
pre-dialysis patients (17), patients with acute dyspnea (9, 29),
stable ischemic heart disease (3, 14, 16), heart failure (30)
or peripheral artery disease (31), and in those with various
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Figure 3 Association between NT-proBNP and eGFR for three
important decision points: 125 pg/mL is the approved decision point
for the exclusion of LVD; 193.5 pg/mL is the 97.5th percentile of
a healthy reference population; 300 pg/mL is the decision point for
ruling out acute CHF in the ER.
stages of renal function (32), and is in contrast to pooled
data which suggested that there is no interdependence
between renal impairment and increased NT-proBNP con-
centrations (33). However, unlike previous studies, our study
was specifically designed to resolve the relationship between
eGFR and NT-proBNP concentrations by using careful pro-
spective patient stratification. The stratification procedure
allowed us to correlate data over a broad and mostly evenly
distributed range of eGFR values, whereas observational
studies underrepresented patients with renal impairment.
Therefore, our study demonstrates that renal function affects
NT-proBNP concentrations beyond cardiac structural abnor-
malities that are frequently present in CKD. Also, it is the
first to provide an algorithm for adjusting marker concentra-
tions for this frequent and important comorbidity.
Effect of adjustment of NT-proBNP for renal
dysfunction
Adjustment of NT-proBNP for eGFR according to the pro-
posed formula results in decreased NT-proBNP concentra-
tions in male subjects with reduced eGFR. This also results
in a decreased scatter of marker-concentrations with less
overlap between the cardiac subgroups and better distinction
between healthy patients (CTRL) and those with structural
heart disease (History and LVH) and LVD (Figure 2).
The effect of adjustment of NT-proBNP upon the predic-
tive value was tested in patients with LVD and symptomatic
LVD, both for the reference value as well as for an optimized
cut-point yielding highest sensitivity and specificity as deter-
mined from ROC analysis. All findings demonstrate that
adjustment of NT-proBNP for eGFR is associated with a
marked and statistically significant improvement in the pre-
dictive value (Table 4). At the reference cut-point, unadjusted
NT-proBNP provides an extremely high negative predictive
value (NPV) for both LVD and symptomatic LVD (Table 4,
rows 1 and 5). This indicates that NT-proBNP reliably
excludes the presence of (symptomatic) LVD at below-
threshold concentrations, and underscores its role as an
important cardiac marker. Since the proposed algorithm
decreases the measured NT-proBNP concentrations in sub-
jects with renal insufficiency, it might cause marker concen-
trations to be adjusted from elevated to normal. If this
reclassification resulted in inappropriate values, it would
result in a loss of NPV. However, as indicated in Table 4
(rows 3 and 7), adjustment of NT-proBNP was not associated
with any loss of negative predictive value, indicating that the
adjustment is appropriate and does not impair the power of
NT-proBNP to exclude LVD. Also, adjustment of NT-pro-
BNP was associated with an increase in specificity of;20%
both for LVD and symptomatic LVD, without any loss in
sensitivity (Table 4, compare rows 1 with 3 and 5 with 7,
respectively). The increase in specificity is equivalent to a
decrease in unspecific test-results, which indicates that
renal insufficiency may cause increased NT-proBNP
concentrations.
The increase in NT-proBNP with decreasing eGFR is
depicted in Figure 3, where the adjustment curves for 3 pop-
ular cut points are plotted against eGFR. These cut-off
thresholds are 125 pg/mL which represents the approved cut-
point for the exclusion of LVD, 193.5 pg/mL which is the
cut-point for our healthy reference population, and 300
pg/mL which is the rule out cut-point for acute congestive
heart failure (CHF) (10). The adjusted curves demonstrate
that when eGFR decreases, NT-proBNP concentrations
increase exponentially and might indicate pathological con-
centrations if no adjustment is performed.
Importance of renal dysfunction
CKD is a predictor of poor prognosis in asymptomatic
patients as well as patients with symptomatic cardiac disease
or heart failure (14, 18–23). It is likely that cardiac markers
will be measured more frequently in patients at risk, but as
the current study confirms, will require careful interpretation
of individual test results. While a reduction in eGFR may
not be as important if significant cardiac disease with LVD
is present, it may be crucial for the interpretation of plasma
concentrations in individuals without any cardiac abnormal-
ities. In these patients, false positive test results will be gen-
erated if the contribution of renal dysfunction on NT-proBNP
concentrations is neglected. The relevance of adjustment of
NT-proBNP concentrations in patients with CKD is apparent
by the fact that 21% of all patients in the group with renal
dysfunction were reclassified from ‘‘elevated’’ to ‘‘normal’’
NT-proBNP following adjustment.
Mechanism of increased NT-proBNP in renal
dysfunction
The strong correlation between renal insufficiency and plas-
ma NT-proBNP concentrations suggests renal elimination as
a major possible contributor. Indeed, renal elimination of NT-
proBNP, similar to BNP, has been demonstrated by catheter-
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ization studies (34–36). In these studies, the renal
elimination rate was between 15% and 20% for both BNP
and NT-proBNP, and is similar to other bioactive peptides
(37). Impairment in glomerular filtration may then lead to
impaired renal extraction and higher plasma concentrations.
As additional mechanism of increased NT-proBNP and BNP
in renal insufficiency, increased plasma concentrations might
also be partly attributable to fluid overload in these patients.
However, we tried to minimize this problem in the current
study by excluding patients with decompensated heart failure
during the past 4 weeks, and made sure that patients with
decreased eGFR in the control group displayed no clinical
signs of heart failure or volume overload.
Limitations
Despite the stratification of patients and multi-center design,
the current study has limitations. NT-proBNP concentrations
in the group with normal echocardiographic findings and
various degrees of renal impairment may not reflect that of
completely ‘‘healthy’’ controls. Renal disease as well as high
prevalences of diabetes, hypertension, and renal transplan-
tation in this group may impact the molecular biology of the
natriuretic peptides. Further, any such condition may cause
changes in cardiac structure without being detectable by
echocardiography, consequently affecting NT-proBNP con-
centrations. This dilemma cannot be eliminated in a human
study, however. A further limitation is that only male patients
were recruited. Due to the effect of gender on NT-proBNP
concentrations, the algorithm for adjusting NT-proBNP con-
centrations in female subjects may differ and need to be eval-
uated separately. Also, our study does not clarify whether an
adjustment for renal insufficiency improves the prognostic
properties of NT-proBNP. Since increased NT-proBNP is a
predictor of poor prognosis in subjects with LV dysfunction,
and renal dysfunction is a predictor of poor prognosis by
itself, the prognostic information of NT-proBNP in patients
with heart failure may solely not be derived from the asso-
ciation with LV, but also with renal insufficiency.
Conclusions
NT-proBNP plasma concentrations are affected by renal
insufficiency. The current study provides an algorithm for
adjusting NT-proBNP concentrations according to eGFR, and
demonstrates that adjustment markedly improves the predic-
tive value of this marker in male patients. Most importantly,
it helps to increase the specificity of the test without loss of
sensitivity or NPV. Individual NT-proBNP test results should
always be interpreted in the context of renal function.
Acknowledgements
We gratefully acknowledge all staff members from the four study
centers who generously supported the study through screening for
potential participants.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that
there are no conflicts of interest regarding the publication of this
article. The funding source and granting support played no role in
the study design; in the collection, analysis, and interpretation of
data; in the writing of the manuscript; or in the decision to submit
the manuscript for publication.
Research funding: The study was supported by an educational
grant from F. Hoffmann-La Roche, Basel, Switzerland.
Employment or leadership: None declared.
Honorarium: AL, KUE and SH have received speakers honoraria
and additional grant support from Roche.
References
1. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN,
Espiner EA. Immunoreactive amino-terminal pro-brain natri-
uretic peptide (NT-PROBNP): a new marker of cardiac impair-
ment. Clin Endocrinol (Oxf) 1997;47:287–96.
2. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant
P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a
pooled analysis of three European epidemiological studies. Eur
J Heart Fail 2004;6:269–73.
3. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert
H, Holmer S. Effect of compensated renal dysfunction on
approved heart failure markers: direct comparison of brain
natriuretic peptide (BNP) and N-terminal pro-BNP. Hyperten-
sion 2005;46:118–23.
4. Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S,
Neubauer E, Puschendorf B, et al. Natriuretic peptides as mark-
ers of mild forms of left ventricular dysfunction: effects of
assays on diagnostic performance of markers. Clin Chem 2004;
50:1174–83.
5. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Pus-
chendorf B, Mair J. Head-to-head comparison of N-terminal
pro-brain natriuretic peptide, brain natriuretic peptide and N-
terminal pro-atrial natriuretic peptide in diagnosing left ven-
tricular dysfunction. Clin Chim Acta 2001;310:193–7.
6. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-ter-
minal pro-brain natriuretic peptide for discriminating between
cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;
6:63–70.
7. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC,
Schultheiss HP. The role of NT-proBNP in the diagnostics of
isolated diastolic dysfunction: correlation with echocardio-
graphic and invasive measurements. Eur Heart J 2005;26:
2277–84.
8. Falkensammer G, Lechleitner P, Hammerer-Lercher A, Theurl
A, Puschendorf B, Mair J. B-type natriuretic peptide and N-
terminal pro brain natriuretic peptide are related to systolic and
diastolic left ventricular function assessed by radionuclide ven-
triculography. Int J Cardiol 2005;105:340–1.
9. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen
AA, Krauser DG, et al. The N-terminal Pro-BNP investigation
of dyspnea in the emergency department (PRIDE) study. Am J
Cardiol 2005;95:948–54.
10. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A,
Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for
diagnosis and short-term prognosis in acute destabilized heart
failure: an international pooled analysis of 1256 patients: the
128 Luchner et al.: Adjustment of NT-proBNP for eGFR
Article in press - uncorrected proof
International Collaborative of NT-proBNP Study. Eur Heart J
2006;27:330–7.
11. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L,
Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide
(NT-proBNP) in the emergency diagnosis and in-hospital mon-
itoring of patients with dyspnoea and ventricular dysfunction.
Eur J Heart Fail 2004;6:301–8.
12. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nich-
olls MG, Richards AM. Brain natriuretic peptide and n-terminal
brain natriuretic peptide in the diagnosis of heart failure in
patients with acute shortness of breath. J Am Coll Cardiol
2003;42:728–35.
13. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K,
McDonagh T, et al. The diagnostic accuracy of plasma BNP
and NTproBNP in patients referred from primary care with sus-
pected heart failure: results of the UK natriuretic peptide study.
Eur J Heart Fail 2005;7:537–41.
14. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann
M, Riegger GA, et al. N-terminal pro-brain natriuretic peptide
after myocardial infarction: a marker of cardio-renal function.
Hypertension 2002;39:99–104.
15. Luchner A, Hengstenberg C, Lowel H, Buchner S, Schunkert
H, Riegger GA, et al. NT-ProBNP in outpatients after myocar-
dial infarction: interaction between symptoms and left ventric-
ular function and optimized cut-points. J Card Fail 2005;11:
S21–7.
16. Richards M, Nicholls MG, Espiner EA, Lainchbury JG,
Troughton RW, Elliott J, et al. Comparison of B-type natriuretic
peptides for assessment of cardiac function and prognosis in
stable ischemic heart disease. J Am Coll Cardiol 2006;47:
52–60.
17. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson
ME, et al. B-type natriuretic peptide (BNP) and amino-terminal
proBNP in patients with CKD: relationship to renal function
and left ventricular hypertrophy. Am J Kidney Dis 2005;46:
610–20.
18. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD,
Kober L, Rouleau JL, et al. Relation between renal dysfunction
and cardiovascular outcomes after myocardial infarction. N
Engl J Med 2004;351:1285–95.
19. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal
insufficiency and heart failure: prognostic and therapeutic
implications from a prospective cohort study. Circulation 2004;
109:1004–9.
20. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP,
et al. Effect of elevated admission serum creatinine and its
worsening on outcome in hospitalized patients with decompen-
sated heart failure. Am J Cardiol 2004;94:957–60.
21. Varghese K, Cherian G, Abraham UT, Hayat NJ, Johny KV.
Predictors of coronary disease in patients with end stage renal
disease. Ren Fail 2001;23:797–806.
22. Parfrey PS, Foley RN. The clinical epidemiology of cardiac
disease in chronic renal failure. J Am Soc Nephrol 1999;10:
1606–15.
23. Baigent C, Burbury K, Wheeler D. Premature cardiovascular
disease in chronic renal failure. Lancet 2000;356:147–52.
24. Cockroft D, Gault M. Prediction of creatinine clearance from
serum creatinine. Nephron 1976;16:31–41.
25. Botev R, Mallie JP, Couchoud C, Schuck O, Fauvel JP, Wetzels
JF, et al. Estimating glomerular filtration rate: Cockcroft-Gault
and Modification of Diet in Renal Disease formulas compared
to renal inulin clearance. Clin J Am Soc Nephrol 2009;4:
899–906.
26. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography: results of
a survey of echocardiographic measurements. Circulation
1978;58:1072–83.
27. Devereux RB, Koren MJ, de Simone G, Okin PM, Kligfield P.
Methods for detection of left ventricular hypertrophy: appli-
cation to hypertensive heart disease. Eur Heart J 1993;14(Suppl
D):8–15.
28. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R,
Feigenbaum H, et al. Recommendations for quantitation of the
left ventricle by two-dimensional echocardiography. American
Society of Echocardiography Committee on Standards, Sub-
committee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiog 1989;2:358–67.
29. Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D,
Ekindjian OG. Influence of renal function on N-terminal pro-
brain natriuretic peptide (NT-proBNP) in patients admitted for
dyspnoea in the emergency department: comparison with brain
natriuretic peptide (BNP). Clin Chim Acta 2005;361:167–75.
30. Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hell-
mich M, Erdmann E, et al. Prognostic impact of NT-proBNP
and renal function in comparison to contemporary multi-marker
risk scores in heart failure patients. Eur J Heart Fail 2008;10:
315–20.
31. Goei D, Schouten O, Boersma E, Welten GM, Dunkelgrun M,
Lindemans J, et al. Influence of renal function on the usefulness
of N-terminal pro-B-type natriuretic peptide as a prognostic
cardiac risk marker in patients undergoing noncardiac vascular
surgery. Am J Cardiol 2008;101:122–6.
32. Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A,
McGuire DK, et al. Association between renal function and
circulating levels of natriuretic peptides (from the Dallas Heart
Study). Am J Cardiol 2008;102:1394–8.
33. Herrmann Z, Uhl W, Steinberg HW, Dworschack R. The influ-
ence of renal function on NT-proBNP levels in various disease
groups. Clin Lab 2003;49:649–56.
34. Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga
CC, Nielsen HB, et al. Kidneys extract BNP and NT-proBNP
in healthy young men. J Appl Physiol 2005;99:1676–80.
35. Goetze JP, Jensen G, Moller S, Bendtsen F, Rehfeld JF, Hen-
riksen JH. BNP and N-terminal proBNP are both extracted in
the normal kidney. Eur J Clin Invest 2006;36:8–15.
36. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle
TG, Richards AM. Regional plasma levels of cardiac peptides
and their response to acute neutral endopeptidase inhibition in
man. Clin Sci (Lond) 1998;95:547–55.
37. Henriksen JH, Schwartz TW, Bulow JB. Endogenous pancreatic
polypeptide in different vascular beds: relationship to release
and degradation in subjects with normal and decreased kidney
function. Metabolism 1986;35:542–6.
